Stauprimide is a semi-synthetic analogue of the staurosporine family of indolocarbazoles. Stauprimide was first published in 1994 as part of an extensive structure-activity investigation to improve the selective inhibition of protein kinase C as potential antitumor agents. Stauprimide increases the efficiency of the directed differentiation of mouse and human embryonic stem cells in synergy with defined extracellular signalling cues. Stauprimide interacts with NME2 (PUF) transcription factor to down-regulate c-Myc expression, leading to differentiation of stem cells.